Previous 10 | Next 10 |
Kala Pharmaceuticals ( KALA ) +65% as FDA oks application for corneal defect treatment . Akoustis Technologies ( NASDAQ: AKTS ) +12% . on receiving First 5G Mobile BAW Filter Design Win from Tier-1 RF Component Company . F-star Therapeutics ( NASDAQ: FSTX ...
XBAW RF Filter Solution Will Ship with New Wafer-Level-Package (WLP) Manufactured in its New York Fab Filter Solution to be Incorporated in Multiplexer for 5G Mobile Handsets and other Portable Devices Multiplexer Supports Major Mobile Chipset Reference Design, Expected to be Rele...
Technology Qualification of Akoustis’ Internally Developed and Manufactured WLP Complete Two Tier-1 5G Mobile RF and First Timing Control Customers Have Accepted New WLP Technology and Packages First Products Leveraging WLP Technology Expected to Ramp Production in Early Ca...
Wi-Fi NOW Supports and Promotes All Things Wi-Fi to Make High-Quality, High-Performance W-Fi Available to Everyone, Everywhere Akoustis Adds to Wi-Fi NOW’s Growing, Global Thought Leadership Charlotte, N.C., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Akoustis Technologies,...
Summary My bullishness on Akoustis Technology has not panned out (so far). I'm personally underwater in the stock. But I'm not selling because the growth thesis is firmly intact. The maker of patented XBAW filter technology recently reported Q1 FY23 revenue growth of 195% yoy whil...
Akoustis Technologies, Inc. (AKTS) Q1 2023 Earnings Conference Call November 14, 2022, 08:00 AM ET Company Participants Tom Sepenzis - Vice President of Corporate Development and Investor Relations Jeff Shealy - Founder and Chief Executive Officer Ken Boller - Ch...
Akoustis Technologies press release ( NASDAQ: AKTS ): Q1 Non-GAAP EPS of -$0.28 misses by $0.05 . Revenue of $5.57M (+199.5% Y/Y) beats by $0.01M . Ramp in XBAW Filter Revenue Expected to Continue in the Current Q2 FY23 with an Estimated Greater than 100% Year-...
Ramp in XBAW Filter Revenue Expected to Continue in the Current Q2 FY23 with an Estimated Greater than 100% Year-Over-Year Revenue Increase Akoustis Now has Fifteen Customers in Production with Finished XBAW Filter Products Customer Activity Remains Robust with E...
Akoustis Technologies ( NASDAQ: AKTS ) is scheduled to announce Q3 earnings results on Friday, November 11th, after market close. The consensus EPS Estimate is -$0.23 (-53.3% Y/Y) and the consensus Revenue Estimate is $5.56M (+122.4% Y/Y). Over the last 1 year, AKTS ...
The 11 th Annual ROTH Technology Event – November 16, 2022 The 13 th Annual Craig-Hallum Alpha Select Conference – November 17, 2022 The 11 th Annual Benchmark Discovery Conference – December 1, 2022 Arete Tech Conference ...
News, Short Squeeze, Breakout and More Instantly...
Akoustis Technologies Inc. Company Name:
AKTS Stock Symbol:
NASDAQ Market:
Akoustis Technologies Inc. Website:
2024-07-10 06:20:00 ET 3 Key Tips to Investing in Biotech Penny Stocks in 2024 Investing in biotech penny stocks offers an exciting opportunity to capitalize on the rapid advancements in medical and healthcare technologies. These small-cap stocks often belong to companies that are d...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) fell 9.3% to $0.2448 on volume of 58,139,351 shares NVIDIA Corporation (NVDA) rose 2.9% to $131.9 on volume of 38,975,630 shares Soligenix Inc. (SNGX) rose 189.2% to $5.784 on volume of 36,915,609...
Tier-1 Customer to Utilize Multiple XBAW ® Filters for Wi-Fi 6E and 7 Access Points Volume Orders to Satisfy Customer’s Demand Through Fiscal Year 2025 Charlotte, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis...